Druggable genome: Genome-wide association to the clinic

Using phenome-genome , expression and pathway mapping approaches, druggable targets were identified from the human genome. These targets were subjected to chemogenomics approaches and lead compounds and secretome proteins were identified for diverse therapeutic areas including cancer, diabetes, Ebola virus disease, neurodegenerative diseases and vitiligo.

Go to the profile of Ramaswamy Narayanan
Apr 29, 2016
Page of
Go to the profile of Ramaswamy Narayanan

Ramaswamy Narayanan

Professor, Biological Sciences, Florida Atlantic University, Boca Raton, FL

I am a biochemist/molecular biologist and a cancer researcher. A Ph.D. in biochemistry from the National University of Ireland, Dublin, I have worked in federal institutions (NIH & CDC), in academia (Yale University & Memorial Sloan Kettering Cancer Center) and in industry (Hoffmann-La Roche AG). For the last 18 years, I have been at the Florida Atlantic University as a Professor in Biology. My research interests are interdisciplinary across the fields of biology, chemistry, engineering and medicine. Over the last three decades, my research has revolved around drug target(s) discovery by mining the human genome using bioinformatics. I am focusing on the areas of druggable targets/chemical leads discovery and repurposed medicine for various therapeutic areas to facilitate accelerated drug discovery and development.

No comments yet.